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Background: Several studies have confirmed the advantages of delivering high doses of external beam
radiotherapy to achieve optimal tumor-control outcomes in patients with localized prostate cancer. We evaluated
the medium-term treatment outcome after high-dose, image-guided intensity-modulated radiotherapy (IMRT) using
intra-prostate fiducial markers for clinically localized prostate cancer.
Methods: In total, 141 patients with localized prostate cancer treated with image-guided IMRT (76 Gy in 13 patients
and 80 Gy in 128 patients) between 2003 and 2008 were enrolled in this study. The patients were classified
according to the National Comprehensive Cancer Network-defined risk groups. Thirty-six intermediate-risk patients
and 105 high-risk patients were included. Androgen-deprivation therapy was performed in 124 patients (88%) for a
median of 11 months (range: 2–88 months). Prostate-specific antigen (PSA) relapse was defined according to the
Phoenix-definition (i.e., an absolute nadir plus 2 ng/ml dated at the call). The 5-year actuarial PSA relapse-free
survival, the 5-year distant metastasis-free survival, the 5-year cause-specific survival (CSS), the 5-year overall survival
(OS) outcomes and the acute and late toxicities were analyzed. The toxicity data were scored according to the
Common Terminology Criteria for Adverse Events, version 4.0. The median follow-up was 60 months.
Results: The 5-year PSA relapse-free survival rates were 100% for the intermediate-risk patients and 82.2% for the
high-risk patients; the 5-year actuarial distant metastasis-free survival rates were 100% and 95% for the intermediate-
and high-risk patients, respectively; the 5-year CSS rates were 100% for both patient subsets; and the 5-year OS
rates were 100% and 91.7% for the intermediate- and high-risk patients, respectively. The Gleason score (<8 vs. ≥8)
was significant for the 5-year PSA relapse-free survival on multivariate analysis (p = 0.044). There was no grade 3 or
4 acute toxicity. The incidence of grade 2 acute gastrointestinal (GI) and genitourinary (GU) toxicities were 1.4% and
8.5%, respectively. The 5-year actuarial likelihood of late grade 2–3 GI and GU toxicities were 6% and 6.3%,
respectively. No grade 4 GI or GU late toxicity was observed.
Conclusions: These medium-term results demonstrate a good tolerance of high-dose image-guided IMRT.
However, further follow-up is needed to confirm the long-term treatment outcomes.
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Table 1 Patient characteristics
Age (y) Median (range) 71 (50–83)
N %
T stage T1 34 24
T2 40 28
T3 67 48
Gleason score <8 73 52
8 − 10 68 48
Initial PSA ≤20 93 66
>20 48 34
NCCN riskGroup IR 36 26
HR 105 74









Abbreviations: PSA, prostate-specific antigen; NCCN, national comprehensive
cancer network; IR, intermediate risk; HR, high risk; ADT, androgen-deprivation
therapy; STADT, short-term ADT; LTADT, long-term ADT.
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Recently, several studies have confirmed the advantages
of delivering high doses of external beam radiotherapy
(EBRT) to achieve optimal tumor-control outcomes in
patients with localized prostate cancer. It is now clear
that conventional EBRT doses in the range of 70 Gy
are not sufficient to eradicate local prostate disease
[1,2]. In addition, a higher EBRT dose requires greater
accuracy and precision. Thus, various position verifica-
tion methods, including image-guided radiotherapy,
have been developed, and their effectiveness has been
reported [3]. However, there are few publications
regarding the treatment outcome after completion of
the delivery of high-doses with image-guided intensity-
modulated radiotherapy (IMRT) using daily intra-
prostatic fiducial marker-based position verification for
localized prostate cancer [4].
We investigated the medium-term treatment out-
comes, including the 5-year prostate-specific antigen
(PSA) relapse-free survival rate, the 5-year distant
metastasis-free survival rate, the 5-year cause-specific
survival (CSS) rate, the 5-year overall survival (OS) rate
and the toxicity outcomes, after high-dose image-guided
IMRT using daily intra-prostatic fiducial markers in
patients with clinical localized prostate cancer.
Methods
Between 2003 and 2008, 150 patients with localized
prostate cancer were treated with image- guided IMRT
at Tohoku University Hospital. Among these patients,
141 patients who satisfied the eligibility criteria were
included in the current study and retrospectively
analyzed.
Eligibility criteria
The eligible patients had a biopsy-confirmed adenocarcin-
oma of the prostate with the clinical stage T1-3N0M0 and
were classified in the National Comprehensive Cancer
Network (NCCN)-defined (www.nccn.com) intermediate-
or high-risk groups. Each patient received magnetic reson-
ance imaging before the initial treatment to exclude lymph
node metastasis and for the staging procedure. Patients
with T2b or T2c clinical stage tumors, a Gleason score
(GS) of 7, or a pretreatment PSA level between 10 and
20 ng/mL were classified as intermediate-risk disease.
Patients who had tumors with a T3a clinical stage or
higher, a GS ≥8, or a pretreatment PSA level >20 ng/mL
were classified as having high-risk disease.
Exclusion criteria
NCCN-defined low-risk patients with a T1-2a clinical
stage tumor, a GS <7, a pretreatment PSA level <10 ng/
mL, and N1 disease were not enrolled in this study.
Patients with a T4 clinical stage tumor, the presence ofmetastasis, other concurrent invasive cancers, or active
collagen disease were also not included. Additionally,
patients with salvage intent were not enrolled, including
patients with a biochemical relapse following a prior
prostatectomy, prior pelvic radiotherapy, and hormonal
therapy. Patients with a follow-up period within 1 year
were also not registered in this analysis.
A total of 105 patients with high-risk localized prostate
cancer and 36 patients with intermediate-risk localized
prostate cancer received IMRT up to a prescribed dose
of 76 Gy or 80 Gy and were investigated. The patient
characteristics are listed in Table 1. Pelvic lymph node
dissection (PLND) was performed in 45 patients (32%)
to rule out metastatic disease.
All eligible patients provided written informed consent
before treatment. The institutional research ethics board
approved this study.
Radiotherapy
The detailed techniques for IMRT treatment planning
and delivery have been previously reported [5]. Briefly,
each patient was implanted with three gold fiducial mar-
kers in the prostate gland before the treatment-planning
computerized tomography (CT) scan was acquired. All
patients were immobilized in the supine position with a
vacuum bag system for their entire body. Since January
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identification of the urethra on radiotherapy-planning
CT images and for contouring the urethra after image
acquisition. The CT scans were then performed at a 2.5-
mm slice thickness. In the IMRT planning, Eclipse (re-
lease 6.5; Varian medical Systems, Palo Alto, CA, USA)
was used for dose calculations. The clinical target vol-
ume (CTV) included the prostate and seminal vesicles.
To adequately encompass the extent of tumor invasion
in the seminal vesicles, the CTV involved the base of the
seminal vesicles in T1-3a patients and more distal to en-
tire portion of the seminal vesicles in T3b patients, re-
spectively. Based on our previous study [6], the CTV
was expanded in three dimensions with a 0.5-cm margin
to obtain the planning target volume (PTV) with the ex-
ception of the prostate–rectum interface, where a 0.3-
cm margin was adopted to decrease rectal involvement.
A portion of the rectal wall located at the level of the
PTV and 0.5 cm outside of the PTV on the CT images
was contoured. The rectum, bladder, bowel, and femur
were contoured as critical normal tissue structures. The
rectal wall was defined with a 2-mm internal wall extrac-
tion. The bladder was entirely contoured, and a 5-mm
inner wall defined the bladder wall volume.
IMRT was delivered using 15MV photons generated
by a Clinac 23 EX linear accelerator (Varian medical Sys-
tems, Palo Alto, CA). The standard 5–8 coplanar beams
were used. The prescribed dose used to cover 95% of the
target volume (D95) was 76 Gy in 13 patients and 80 Gy
in 128 patients. A total dose of 76 Gy in 2-Gy daily frac-
tions was delivered to 13 patients who had other prior
severe diseases, including diabetes or cardiovascular dis-
orders. The maximum dose heterogeneity allowable in
the PTV was 10%. Each treatment plan was optimized
to ensure the following conditions: no more than 65% of
the rectal and urinary bladder wall received >35 Gy
(V35 ≤ 65%); no more than 45% of the rectal and urinary
bladder wall received >55 Gy (V55 ≤ 45%); no more than
25% of the rectal and urinary bladder wall received
>75 Gy (V75 ≤ 25%); and the urethral, rectal, and bladder
walls received no more than 80 Gy. In the overlap region
between the PTV and these critical organs, the con-
straint was set to 95% of the prescription dose for the
rectum and 95% for the urethra. The latter dose con-
straint for the urethra has been applied to 108 patients
since January 2004.
In addition, prior to the acquisition of the treatment
planning CT images and 30 minutes before the daily
IMRT, each patient urinated to ensure the bladder was
in the same state. In addition, the patients emptied their
bowels just before the daily IMRT. For every treatment
fraction, the patients were initially prepared using laser
marks on their skin, and they were then repositioned
using the Varian On-Board Imager based on thepositions of the three intra-prostatic fiducial markers,
and the precision-of-position verification was within
1 mm. We did not find any instances of fiducial migra-
tion during treatment. All patients were treated to their
prescribed dose in daily 2.0 Gy fractions. The imaging
dose was not accounted for in the treatment plans.
Hormonal therapy
Androgen-deprivation therapy (ADT) was used at the
discretion of the treating physician. ADT primarily con-
sisted of an oral anti-androgen and luteinizing hormone-
releasing hormone agonist administered as depot injec-
tions. In 124 patients receiving ADT, the median ADT
duration was 11 months (range: 2–88 months). Among
these patients, 44 (35%) received only neoadjuvant ADT,
and the other 80 (65%) were treated with neoadjuvant
ADT, concurrent and adjuvant ADT. Table 1 shows the
details of the ADT duration. ADT was classified as
short-term (STADT) if it was administered for
≤6 months and long-term (LTADT) if it was adminis-
tered for >6 months. The median duration of ADT in
the 24 intermediate-risk and 100 high-risk patients was
5 months (range: 4–32 months) and 12 months (range:
2–88 months), respectively. The details of STADT and
LTADT are as follows: for the 24 intermediate-risk
patients, there were 10 STADT and 14 LTADT, and for
the 100 high-risk patients, there were 17 STADT and 83
LTADT. The median duration between the initiation of
ADT and the start of IMRT was 8 months (range: 1–
36 months).
After treatment follow-up evaluation
Follow-up evaluations after the completion of treatment
were performed at 3- to 6-month intervals for 5 years
and every 6 months thereafter. The median follow-up
was 66 months (range: 17–111 months).
Freedom from biochemical relapse was analyzed using
the Phoenix consensus definition (i.e., an absolute nadir
PSA level plus 2 ng/mL more than the recorded level)
[7,8]. For CSS analysis, patients with documentation of
biochemical or metastatic relapsed disease who subse-
quently died were scored as deaths from localized pros-
tate cancer.
Acute and late toxicity data were scored according to
the National Cancer Institute-designated Common Ter-
minology Criteria for Adverse Events Version 4.0.
Statistical analyses
The distributions of the 5-year PSA relapse-free survival
were calculated using Kaplan–Meier curves for biochem-
ical control using the one failure definition. The 5-year ac-
tuarial distant metastasis-free survival, CSS, and OS rates
were also evaluated by Kaplan–Meier curves. Univariate
analyses (UA) and multivariate analyses (MA) were
Table 2 Statistical analyses of predictors for the 5-year
PSA relapse-free survival, p values
UA MA
NCCN risk (IR vs. HR) 0.01* 0.96
GS (8–10 vs. < 8) <0.001* 0.044*
ADT (yes vs. no) 0.1 0.967
ADT duration (continuous) 0.452 0.549
STADT vs. LTADT 0.477 0.513
Pretreatment PSA (≤20 vs. >20) 0.046* 0.29
PLND (yes vs. no) 0.316 0.454
Abbreviations: UA, univariate analysis; MA, multivariate analysis; *, statistical
significance; PLND, pelvic lymph node dissection; other abbreviations as in
Table 1.
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vival predictors (i.e., NCCN risk stratification, GS, ADT
use and duration, STADT, LTADT, pretreatment PSA, and
PLND) and the late gastrointestinal (GI) and genitourinary
(GU) side effects ≥ grade 2 (i.e., age, ADT use, duration
between ADT initiation and the start of IMRT, the pres-
ence of diabetes, hypertension, hemorrhoids, acute grade
2 GI and GU toxicities, and prescribed RT dose). MA was
performed using a Cox regression model. Statistical ana-
lyses were performed using the Statistical Package for So-
cial Sciences for Windows, version 20. A p-value <0.05




The 5-year actuarial PSA relapse-free survival outcomes
for the intermediate- and high-risk groups were 100 and
82.2%, respectively [Figure 1], and the NCCN risk classi-
fication, GS, and pretreatment PSA were significant in
UA, whereas only the GS was statistically significant
variable in MA [Table 2].
Distant metastasis-free survival, cause-specific survival
and overall survival rates
Distant metastases developed in four (2.8%) patients.
The 5-year actuarial distant metastasis-free survival rates
for the intermediate- and high-risk groups were 100 andLog-rank P-value = 0.01
Figure 1 Phoenix consensus definition PSA relapse-free survival by N
national comprehensive cancer network.95%, respectively [Figure 2]. The 5-year CSS rates for
the intermediate- and high-risk patients were both
100%. The 5-year OS rates for the intermediate- and
high-risk patients were 100 and 91.7%, respectively.
Toxicity
Grades 1 and 2 GI acute toxicity were identified in 29
(20%) and 2 (1.4%) patients, respectively. Grades 1 and 2
acute GU toxicities occurred in 84 (60%) and 12 (8.5%)
patients, respectively. There was no acute GI and GU
toxicity grade 3 or higher.
Late grade 2 or 3 GI toxicities developed in eight
patients (5.7%) at a median of 18 months after image-CCN risk group. Abbreviations: PSA, prostate-specific antigen; NCCN,
Figure 2 The Kaplan-Meier curve illustrates the actuarial probability of achieving distant metastasis-free survival.
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patients and proctitis in one patient. Rectal hemorrhage
as a grade 3 late GI toxicity occurred in two patients
who were treated with several transfusions and a laser
cauterization procedure. No grade 4 or greater GIFigure 3 Kaplan-Meier actuarial probability of late grade 2 or 3 GI ancomplications were observed. The 5-year actuarial likeli-
hood of late grade 2 or 3 GI toxicities was 6% [Figure 3].
In UA, the group without ADT was related to grade 2 or
3 late GI toxicities, whereas that relationship was not
significant in MA [Table 3]. In addition, the durationd GU toxicities. Abbreviations: GI, Gastrointestinal; GU, Genitourinary.
Table 3 Statistical analyses of predictors for late toxicity,
p values
Late grade 2 or
3 GI toxicity
Late grade 2 or
3 GU toxicity
UA MA UA MA
Age (>71) 0.414 0.42 0.078 0.039*
ADT 0.025* 0.401 0.889 0.314
Duration between ADT
initiation and the start
of IMRT
0.088 0.619 0.522 0.312
Diabetes 0.526 0.877 0.66 0.511
Hypertension 0.396 0.474 0.38 0.732
Hemorrhoid 0.952 0.853 NA NA
Acute grade 2 GI toxicity 0.743 0.992 NA NA
Acute grade 2 GU toxicity NA NA <0.001* 0.001*
76 Gy vs. 80 Gy 0.77 0.716 0.291 0.987
Abbreviations: GI, gastrointestinal; GU, genitourinary; NA, not applicable; other
abbreviations as in Tables 1–2.
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not statistically significant for late GI toxicities grade 2
or 3 [Table 3].
Late grade 2 or 3 GU toxicities developed in nine
patients (6.4%) at a median of 30 months after image-
guided IMRT. There was urinary retention in four
patients, urinary frequency in two patients, urinary tract
obstruction in one patient, urgency in one patient and
non-infective cystitis in one patient. No grade 4 orTable 4 Literature review
RT dose (Gy) ADT rate (%)
Alicikus et al. [1] 81 LR 54 (total)
IR
HR
Martin et al. [4] 79.8 LR 13.6
IR 11.0
HR 45.9






Cahlon, et al. [16] 86.4 LR 66 (total)
IR
HR
Current study 80 or 76 IR 67
HR 95
Abbreviations: RT, radiotherapy; M, months; LR, low risk; PD, Phoenix Consensus def
definition; other abbreviations as in Table 1.greater GU toxicity was observed. The 5-year actuarial
likelihood of late grade 2 or 3 GU toxicities was 6.3%
[Figure 3]. In UA and MA, acute grade 2 GU toxicity
was predictive of late grade 2 or 3 GU toxicities [Table 3].
Although age (>71) was not significant in UA, it was
predictive in the MA [Table 3].
Discussion
Our results show that high-dose image-guided IMRT can
be safely performed and is well tolerated. This study also
demonstrated relatively few biochemical failures after
image-guided IMRT in patients with intermediate- and
high-risk localized prostate cancer as a medium-term
period assessment [Table 4]. Nevertheless, it is difficult to
tell whether this was a function of high-dose image-guided
IMRT, heterogeneity within this series of patients, differ-
ent hormonal therapies, or any combination of these
factors.
There is clear support for dose escalation in prostate
cancer radiotherapy. Several studies have confirmed that
74- to 81-Gy doses provided a 15-20% improvement in
biochemical control compared with conventional doses
of <70 Gy [9-12]. According to previous studies, bio-
chemical tumor-control rate improvement will lead to
better distant metastasis-free survival and CSS [13-15].
The current distant metastasis-free survival and CSS
rates were at least equivalent to other reports, although
direct comparison with other publications is difficult
due to differences in the follow-up periods [1,2,12].ADT duration (M) PSA relapse-free survival (%)
3 PD: 10-year 81
78
62
not mentioned PD: 5-year 88.4
76.5
77.9






3 or 9 PD: 5-year 98
85
70
5 (median) (range: 4–32) PD: 5-year 100
12 (median) (range: 2–88) 82.2
inition; AD, American Society for Therapeutic Radiology and Oncology
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tively high rate and long duration of ADT administration
may contribute to the current biochemical tumor-control
outcome, although the effect was not statistically signifi-
cant [Tables 2 and 4] [1,12,16,17]. To our knowledge, few
publications have reported high-dose EBRT with a high
rate and long ADT administration duration that was simi-
lar to this study. Moreover, according to D’Amico et al.
and Bolla et al., the radiotherapy survival benefit may be
improved by adding ADT for high- and intermediate-risk
localized prostate cancer [17,18]. Furthermore, a meta-
analysis of Radiation Therapy Oncology Group prostate
cancer trials demonstrated that STADT appeared to im-
prove the 8-year disease-specific survival for intermediate-
risk patients, whereas LTADT improved the 8-year overall
survival for high-risk patients [19]. According to Alicikus
et al., the lack of a benefit from ADT in their high-risk
patients may have been caused by the relatively short
course of only 5–6 months of ADT in their study [1].
They advocated the use of a longer ADT course, particu-
larly for high-risk patients.
The incidence of late grade ≥2 GI and GU toxicity fol-
lowing high-dose radiotherapy in recent studies ranged
from 3.7 to 22% and from 8.6 to 35%, respectively
[1,4,16,20]. In this report, the likelihood of developing
late grade ≥2 GI and GU toxicities was 6 and 6.3%, re-
spectively, at 5 years. One reason that may explain our
late GI toxicity incidence may be that we did not con-
firm the actual position of the rectum during the entire
IMRT period, although every patient was prepared be-
fore each treatment with minimized bowel contents, in-
cluding gas and stool, which was similar to the
acquisition of treatment-planning CT. Although Smeenk
et al. reported some procedures for reducing the physio-
logical bowel effects, those techniques were not used in
this study [21].
The relationship between ADT administration and late
grade 2–3 GI toxicities was not statistically significant in
MA, whereas there appeared to be a relationship in UA
[Table 3]. In addition, the duration between ADT initi-
ation and the start of IMRT was not correlated with late
GI grade 2 or 3 toxicities [Table 3]. Although there may
be some mechanisms that explain why patients with
ADT administration demonstrated a low tendency for
late grade 2–3 GI toxicities in UA, it is difficult to clar-
ify. This topic is controversial. Several authors reported
that ADT administration increases late GI toxicity
[20,22]. In contrast, other studies have indicated lower
GI and GU toxicity rates when ADT was added to EBRT
for localized prostate cancer [23,24]. Longer follow-up
and further investigation are needed.
The incidence of late grade 2–3 GU toxicities
appeared to be lower than that previously reported
[1,4,16,20]. Several reasons may exist. One reason mightbe that we set the urethral dose constraints to reduce
the maximal urethral dose to <80 Gy in patients treated
with 80 Gy since January 2004. Zelefsky et al. indicated
more severe late urinary toxicity following high-dose
IMRT delivering 81.0 Gy or 86.4 Gy [25]. According to
these authors, the 3-year actuarial likelihood of late
grade ≥2 urinary toxicities was 15%. Therefore, we began
setting the urethral dose constraints in 2004. Another
reason might be that our image-guided IMRT had a
precision-of-position verification within 1 mm. However,
further follow-up and examination is necessary to evalu-
ate late GU toxicity and related factors.
In this series, acute grade 2 GU toxicity was statisti-
cally related to late grade 2–3 GU toxicity in the MA
[Table 3]. Alicikus et al. also demonstrated that acute
grade ≥2 GU toxicity was predictive for late grade ≥2
GU toxicity [1]. According to Bolla et al. and Peeters
et al., an increase in late GU toxicity was associated with
LTADT in addition to RT [17,22]. In contrast, similar to
Alicikus et al., the use and duration of ADT was not
related to the late grade 2–3 GU toxicity in this study
[1] [Table 3].
Grade 2 acute GI and GU symptoms developed in two
(1.4%) and 12 patients (8.5%), respectively. There was no
acute GI or GU toxicity of grade 3 or higher. Similar to
Alicikus et al., the acute GI toxicity was minimal [1].
However, the current incidence of acute GU symptoms
was higher than that in their study [1]. Alicikus et al.
reported a grade 2 acute GU toxicity frequency of 3%.
Nevertheless, other studies have indicated higher occur-
rences of grade 2 acute GU toxicity than our study, ran-
ging from 22 to 47% [3,4,16]. Accordingly, our results,
with respect to acute and late GI and GU toxicities, ap-
pear to be favorable.
Several limitations exist in this study. First, this study
had no randomization; therefore, it had an inherent po-
tential for selection bias. Additionally, our sample size
was more limited than some other studies [1,4,12,16].
Second, this analysis included a small number of
patients who were followed for <5 years, which did not
allow an adequate period to evaluate clinical failures or
side effects. The small number of biochemical failures
could be a function of the short follow-up. Third, we un-
fortunately did not estimate sexual function before and
after treatment in this analysis, whereas several authors
have reported a relationship between ADT use and the
development of erectile dysfunction [1,26,27]. However,
we reported the health-related quality of life in smaller
numbers of patients treated with image-guided IMRT
[28], and further investigation is in progress.
Conclusions
We report the medium-term treatment outcomes of high-
dose image-guided IMRT for patients with localized
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and appears to provide valuable biochemical tumor con-
trol. Nevertheless, a relatively high rate and long duration
of ADT administration may have also potentially contribu-
ted to the outcome. Further investigation is needed to
optimize integration between dose-escalated radiotherapy
and adequate ADT. Additionally, longer follow-up is es-
sential to evaluate the long-term treatment outcomes.
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